Friday, November 06, 2015 8:12:37 AM
ROCKVILLE, Md., Nov. 5, 2015 - CASI Pharmaceuticals, Inc. (CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, announces a poster presentation on a Phase 2 study of ENMD-2076 in soft tissue sarcoma (STS) at the 2015 Connective Tissue Oncology Society (CTOS) annual meeting in Salt Lake City, Utah, November 4-7, 2015. To view the poster, visit the Company’s website at http://www.casipharmaceuticals.com.
Rong Chen, M.D., CASI’s Chief Medical Officer, commented, “The Phase 2 study was designed to evaluate clinical activity and safety of ENMD-2076 as a monotherapy in the treatment of metastatic STS in correlation with genetic biomarker(s). The data, presented by the investigators of Princess Margaret Cancer Centre at Toronto University, revealed clinical benefit, either partial response (PR) or stable disease (SD) for more than 6 months, in 17% of patients studied. Genetic variations in CCL11 and FLNB were shown to be potentially associated with the clinical benefit from ENMD-2076, while gene variations in EGFR and CYP4B1 polymorphism could be associated with lack of clinical benefit.”
Dr. Chen further commented, “The findings confirm our rationale that ENMD-2076 may provide clinical benefit to a subset of STS patients, which may lead to the development of personalized target therapy. The identification of potential clinical correlative biomarkers provides valuable information for our continued development of ENMD-2076 in STS. We are on track to initiate our Phase 2 trial for STS in China, which will be conducted under the same protocol and will allow us to investigate and further validate the drug’s clinical activities and correlative biomarkers in an expanded patient population.”
Ken Ren, Ph.D., CASI’s Chief Executive Officer, commented, “Our goal is to reach a clinical inflection point with the identification of correlative biomarker(s) prior to the end of next year so as to support Phase 3 trials in a well-defined subset of STS patients.”
Dr. Ren continued, “We also remain on track with our other clinical trials for ENMD-2076 in triple negative breast cancer (TNBC) and ovarian clear cell carcinoma (OCCC). Enrollment in our China sites for TNBC is currently underway. We remain optimistic about having ENMD-2076 developed as a personized target therapy for STS, TNBC and/or OCCC, as cumulative evidence has shown clinical benefit of the drug in a subset of patients in each of the indications.”
Recent CASI News
- CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS • PR Newswire (US) • 04/08/2024 09:00:00 PM
- CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS • PR Newswire (US) • 03/28/2024 11:00:00 AM
- CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China • PR Newswire (US) • 03/05/2024 12:00:00 PM
- CASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINA • PR Newswire (US) • 02/16/2024 12:00:00 PM
- CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 BUSINESS AND FINANCIAL UPDATES • PR Newswire (US) • 11/14/2023 12:00:00 PM
- CASI PHARMACEUTICALS ANNOUNCES MARKET APPROVAL OF CNCT19 BY CHINA NMPA • PR Newswire (US) • 11/08/2023 12:00:00 PM
- CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATES • PR Newswire (US) • 08/11/2023 11:00:00 AM
- Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals • PR Newswire (US) • 08/01/2023 11:00:00 AM
- CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339 • PR Newswire (US) • 07/20/2023 12:00:00 PM
- CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS • PR Newswire (US) • 05/17/2023 11:35:00 AM
FEATURED Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • Apr 25, 2024 8:52 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM